949 related articles for article (PubMed ID: 19558372)
21. Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.
Kalaitzakis E; Benito de Valle M; Rahman M; Lindkvist B; Björnsson E; Chapman R; Kontodimopoulos N
Qual Life Res; 2016 Apr; 25(4):947-57. PubMed ID: 26471264
[TBL] [Abstract][Full Text] [Related]
22. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis.
Lillegraven S; Kristiansen IS; Kvien TK
Ann Rheum Dis; 2010 Oct; 69(10):1762-7. PubMed ID: 20448285
[TBL] [Abstract][Full Text] [Related]
23. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
[TBL] [Abstract][Full Text] [Related]
24. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.
Harrison MJ; Lunt M; Verstappen SM; Watson KD; Bansback NJ; Symmons DP
Health Qual Life Outcomes; 2010 Feb; 8():21. PubMed ID: 20149253
[TBL] [Abstract][Full Text] [Related]
25. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.
Crott R; Versteegh M; Uyl-de-Groot C
Qual Life Res; 2013 Jun; 22(5):1045-54. PubMed ID: 22743734
[TBL] [Abstract][Full Text] [Related]
26. Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.
Arnold DT; Rowen D; Versteegh MM; Morley A; Hooper CE; Maskell NA
Health Qual Life Outcomes; 2015 Jan; 13():6. PubMed ID: 25613110
[TBL] [Abstract][Full Text] [Related]
27. Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to stand on yet.
Crott R
Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):569-76. PubMed ID: 24910212
[TBL] [Abstract][Full Text] [Related]
28. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
[TBL] [Abstract][Full Text] [Related]
29. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences.
Crott R; Briggs A
Eur J Health Econ; 2010 Aug; 11(4):427-34. PubMed ID: 20473703
[TBL] [Abstract][Full Text] [Related]
30. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
31. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
[TBL] [Abstract][Full Text] [Related]
32. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
33. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
Woodcock F; Doble B;
Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
[TBL] [Abstract][Full Text] [Related]
34. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.
Kim EJ; Ko SK; Kang HY
Qual Life Res; 2012 Sep; 21(7):1193-203. PubMed ID: 22012023
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement.
Xie F; Li SC; Luo N; Lo NN; Yeo SJ; Yang KY; Fong KY; Thumboo J
Arthritis Rheum; 2007 Aug; 57(6):1043-9. PubMed ID: 17665466
[TBL] [Abstract][Full Text] [Related]
36. Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.
Whitehurst DG; Norman R; Brazier JE; Viney R
Value Health; 2014 Jul; 17(5):570-7. PubMed ID: 25128050
[TBL] [Abstract][Full Text] [Related]
37. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis.
Wolfe F; Michaud K; Wallenstein G
J Rheumatol; 2010 Aug; 37(8):1615-25. PubMed ID: 20551106
[TBL] [Abstract][Full Text] [Related]
38. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract][Full Text] [Related]
39. The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.
Kontodimopoulos N
Qual Life Res; 2015 Jun; 24(6):1535-44. PubMed ID: 25391489
[TBL] [Abstract][Full Text] [Related]
40. Estimating EQ-5D values from the Neck Disability Index and numeric rating scales for neck and arm pain.
Carreon LY; Bratcher KR; Das N; Nienhuis JB; Glassman SD
J Neurosurg Spine; 2014 Sep; 21(3):394-9. PubMed ID: 24905392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
